Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: Scarification vaccination

Vaccine

Volumn 26, Issue 23, 2008, Pages 2860-2872

  Jentarra, Garilyn M ^b   Heck, Michael C ^b   Youn, Jin Won ^c   Kibler, Karen ^b   Langland, Jeffrey O ^b   Baskin, Carole R ^b   Ananieva, Olga ^b   Chang, Yung ^a,b   Jacobs, Bertram L ^a,b  

^a ARIZONA STATE UNIVERSITY   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

^c NEW YORK BLOOD CENTER   (United States)

Author keywords

E3L; Smallpox vaccine; Vaccinia

Indexed keywords

LIVE VACCINE; VACCINIA VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; E3L GENE; GENE DELETION; IMMUNE RESPONSE; NONHUMAN; POXVIRUS INFECTION; PRIORITY JOURNAL; SCAR FORMATION; SEVERE COMBINED IMMUNODEFICIENCY; VACCINIA VIRUS; VIRUS GENE; VIRUS MUTATION; VIRUS REPLICATION; VIRUS STRAIN; VIRUS VIRULENCE;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; CELLS, CULTURED; COMET ASSAY; CRICETINAE; CYTOKINES; DRUG RESISTANCE, VIRAL; FEMALE; GENES, VIRAL; IMMUNITY, CELLULAR; INTERFERONS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, SCID; MUTATION; NEUTRALIZATION TESTS; RABBITS; SPLEEN; VACCINES, ATTENUATED; VACCINIA; VACCINIA VIRUS; VIRAL VACCINES; VIRUS REPLICATION;

EID: 43249115539     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.03.044     Document Type: Article

References (36)

1. Fenner F., Henderson D.A., Arita I., and Jezek Z. Ladnyi ID: smallpox and its eradication (1988), World Health Organization, Geneva, Switzerland
2. Cassimatis D.C., Atwood J.E., Engler R.M., Linz P.E., Grabenstein J.D., and Vernalis M.N. Smallpox vaccination and myopericarditis: a clinical review. J Am Coll Cardiol 43 (2004) 1503-1510. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15120802
3. Fulginiti V.A., Papier A., Lane J.M., Neff J.M., and Henderson D.A. Smallpox vaccination: a review. Part II. Adverse events. Clin Infect Dis 37 (2003) 251-271. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12856218
4. Meyer H., Sutter G., and Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J Gen Virol 72 Pt 5 (1991) 1031-1038. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2033387
5. Coulibaly S., Bruhl P., Mayrhofer J., Schmid K., Gerencer M., and Falkner F.G. The nonreplicating smallpox candidate vaccines defective vaccinia Lister (dVV-L) and modified vaccinia Ankara (MVA) elicit robust long-term protection. Virology 341 (2005) 91-101. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16061267
6. Tartaglia J., Perkus M.E., Taylor J., Norton E.K., Audonnet J.C., Cox W.I., et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 188 (1992) 217-232. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1566575
7. Kenner J., Cameron F., Empig C., Jobes D.V., and Gurwith M. LC16m8: an attenuated smallpox vaccine. Vaccine 24 (2006) 7009-7022. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17052815
8. Tartaglia J., Cox W.I., Pincus S., and Paoletti E. Safety and immunogenicity of recombinants based on the genetically-engineered vaccinia strain, NYVAC. Dev Biol Stand 82 (1994) 125-129. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7958466
9. Ramirez J.C., Gherardi M.M., and Esteban M. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J Virol 74 (2000) 923-933. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=10623755
10. Rosenwirth B., Kuhn E.M., Heeney J.L., Hurpin C., Tartaglia J., Bonnet M.C., et al. Safety and immunogenicity of ALVAC wild-type human p53 (vCP207) by the intravenous route in rhesus macaques. Vaccine 19 (2001) 1661-1670. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11166889
11. Meseda C.A., Garcia A.D., Kumar A., Mayer A.E., Manischewitz J., King L.R., et al. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model. Virology 339 (2005) 164-175. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15993917
12. Vollmar J., Arndtz N., Eckl K.M., Thomsen T., Petzold B., Mateo L., et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 24 (2006) 2065-2070. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16337719
13. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292 (2001) 69-74. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11393868
14. Shors S.T., Beattie E., Paoletti E., Tartaglia J., and Jacobs B.L. Role of the vaccinia virus E3L and K3L gene products in rescue of VSV and EMCV from the effects of IFN-alpha. J Interferon Cytokine Res 18 (1998) 721-729
15. Xiang Y., Condit R.C., Vijaysri S., Jacobs B., Williams B.R., and Silverman R.H. Blockade of interferon induction and action by the E3L double-stranded RNA binding proteins of vaccinia virus. J Virol 76 (2002) 5251-5259
16. Chang H.W., Watson J.C., and Jacobs B.L. The E3L gene of vaccinia virus encodes an inhibitor of the interferon-induced, double-stranded RNA-dependent protein kinase. Proc Natl Acad Sci USA 89 (1992) 4825-4829. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1350676
17. Chang H.W., and Jacobs B.L. Identification of a conserved motif that is necessary for binding of the vaccinia virus E3L gene products to double-stranded RNA. Virology 194 (1993) 537-547. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=8099244
18. Colby C., Jurale C., and Kates J.R. Mechanism of synthesis of vaccinia virus double-stranded ribonucleic acid in vivo and in vitro. J Virol 7 (1971) 71-76. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=5543434
19. Pestka S., Langer J.A., Zoon K.C., and Samuel C.E. Interferons and their actions. Annu Rev Biochem 56 (1987) 727-777. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=2441659
20. Sen G.C., and Lengyel P. The interferon system. A bird's eye view of its biochemistry. J Biol Chem 267 (1992) 5017-5020. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1371992
21. Kim Y.G., Muralinath M., Brandt T., Pearcy M., Hauns K., Lowenhaupt K., et al. A role for Z-DNA binding in vaccinia virus pathogenesis. Proc Natl Acad Sci USA 100 (2003) 6974-6979. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12777633
22. Vijaysri S., Jentarra G., Heck M.C., Mercer A.A., McInnes C.J., and Jacobs B.L. Vaccinia viruses with mutations in the E3L gene as potential replication-competent, attenuated vaccines: intra-nasal vaccination. Vaccine 26 (2008) 664-676. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18096276
23. Ludvikova V., Kutinova L., Simonova V., and Otavova M. Evaluation of various virulence tests with low virulence vaccinia virus in mice. Biologicals 22 (1994) 187-190. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7917234
24. Monath T.P., Caldwell J.R., Mundt W., Fusco J., Johnson C.S., Buller M., et al. ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)-a second-generation smallpox vaccine for biological defense. Int J Infect Dis 8 Suppl 2 (2004) S31-S44. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15491873
25. Kibler K.V., Shors T., Perkins K.B., Zeman C.C., Banaszak M.P., Biesterfeldt J., et al. Double-stranded RNA is a trigger for apoptosis in vaccinia virus-infected cells. J Virol 71 (1997) 1992-2003. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9032331
26. He Y., Tan S.L., Tareen S.U., Vijaysri S., Langland J.O., Jacobs B.L., et al. Regulation of mRNA translation and cellular signaling by hepatitis C virus nonstructural protein NS5A. J Virol 75 (2001) 5090-5098. http://jvi.asm.org/cgi/content/abstract/75/11/5090 http://jvi.asm.org/cgi/content/abstract/75/11/5090
27. Brandt T.A., and Jacobs B.L. Both carboxy- and amino-terminal domains of the vaccinia virus interferon resistance gene, E3L, are required for pathogenesis in a mouse model. J Virol 75 (2001) 850-856. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11134298
28. Essbauer S., Bremont M., and Ahne W. Comparison of the eIF-2alpha homologous proteins of seven ranaviruses (Iridoviridae). Virus Genes 23 (2001) 347-359. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11778703
29. Davies M.V., Elroy-Stein O., Jagus R., Moss B., and Kaufman R.J. The vaccinia virus K3L gene product potentiates translation by inhibiting double-stranded-RNA-activated protein kinase and phosphorylation of the alpha subunit of eukaryotic initiation factor 2. J Virol 66 (1992) 1943-1950. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=1347793
30. Brandt T., Heck M.C., Vijaysri S., Jentarra G.M., Cameron J.M., and Jacobs B.L. The N-terminal domain of the vaccinia virus E3L-protein is required for neurovirulence, but not induction of a protective immune response. Virology 333 (2005) 263-270. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=15721360
31. Chang H.W., Uribe L.H., and Jacobs B.L. Rescue of vaccinia virus lacking the E3L gene by mutants of E3L. J Virol 69 (1995) 6605-6608. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7666567
32. Shors T., Kibler K.V., Perkins K.B., Seidler-Wulff R., Banaszak M.P., and Jacobs B.L. Complementation of vaccinia virus deleted of the E3L gene by mutants of E3L. Virology 239 (1997) 269-276. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9434718
33. Vanderplasschen A., Hollinshead M., and Smith G.L. Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation. J Gen Virol 78 Pt 8 (1997) 2041-2048. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=9267005
34. Belyakov I.M., Earl P., Dzutsev A., Kuznetsov V.A., Lemon M., Wyatt L.S., et al. Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci USA 100 (2003) 9458-9463. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=12869693
35. Panchanathan V., Chaudhri G., and Karupiah G. Correlates of protective immunity in poxvirus infection: where does antibody stand?. Immunol Cell Biol 86 (2008) 80-86. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17923850
36. Langland J.O., Kash J.C., Carter V., Thomas M.J., Katze M.G., and Jacobs B.L. Suppression of proinflammatory signal transduction and gene expression by the dual nucleic acid binding domains of the vaccinia virus E3L proteins. J Virol 80 (2006) 10083-10095